Clinical Trial Update: Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients [Phase 2]

View source ↗

Summary

Phase IIa study of MP4OX in traumatic hemorrhagic shock has completed, providing an update on the Phase 2 trial conducted by sponsor Sangart.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhagic Shock
• Lactic Acidosis
• Traumatic Shock

Drugs mentioned

• MP4OX

Snippet

Sponsor: Sangart | Conditions: Shock, Hemorrhagic, Shock, Traumatic | Phase 2 | Status: COMPLETED